Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer

被引:530
|
作者
van Meerbeeck, Jan P.
Kramer, Gijs W. P. M.
Van Schil, Paul E. Y.
Legrand, Catherine
Smit, Egbert F.
Schramel, Franz
Tjan-Heijnen, Vivianne C.
Biesma, Bonne
Debruyne, Channa
van Zandwijk, Nico
Splinter, Ted A. W.
Giaccone, Giuseppe
机构
[1] Ghent Univ Hosp, Dept Resp Med, B-9000 Ghent, Belgium
[2] Arnhem Radiotherapeut Inst, Dept Radiat Therapy, Arnhem, Netherlands
[3] Univ Hosp Antwerp, Dept Resp Med, Antwerp, Belgium
[4] Univ Hosp Antwerp, Dept Thorac Surg, Antwerp, Belgium
[5] European Org Res Treatment Canc, Ctr Data, Brussels, Belgium
[6] Vrije Univ Amsterdam, Dept Pulmonol, Amsterdam, Netherlands
[7] Vrije Univ Amsterdam, Dept Med Oncol, Amsterdam, Netherlands
[8] St Antonius Hosp, Dept Pulmonol, Nieuwegein, Netherlands
[9] Radboud Univ Nijmegen Med Ctr, Dept Med Oncol, Nijmegen, Netherlands
[10] Jeroen Bosch Ziekenhuis, Dept Pulmonol, Shertogenbosch, Netherlands
[11] Netherlands Canc Inst, Dept Thorac Oncol, Amsterdam, Netherlands
[12] Erasmus MC, Dept Pulmonol, Rotterdam, Netherlands
[13] Erasmus MC, Dept Med Oncol, Rotterdam, Netherlands
来源
关键词
D O I
10.1093/jnci/djk093
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Induction chemotherapy before surgical resection increases survival compared with surgical resection alone in patients with stage IIIA-N2 non-small-cell lung cancer (NSCLC). We hypothesized that, following a response to induction chemotherapy, surgical resection would be superior to thoracic radiotherapy as locoregional therapy. Methods Selected patients with histologic or cytologic proven stage IIIA-N2 NSCLC were given three cycles of platinum-based induction chemotherapy. Responding patients were subsequently randomly assigned to surgical resection or radiotherapy. Survival curves were estimated using Kaplan-Meier analyses from time of randomization. Results Induction chemotherapy resulted in a response rate of 61% (95% confidence interval [Cl] = 57% to 65%) among the 579 eligible patients. A total of 167 patients were allocated to resection and 165 to radiotherapy. Of the 154 (92%) patients who underwent surgery, 14% had an exploratory thoracotomy, 50% a radical resection, 42% a pathologic downstaging, and 5% a pathologic complete response; 4% died after surgery. Postoperative radiotherapy was administered to 62 (40%) of patients in the surgery arm. Among the 154 (93%) irradiated patients, overall compliance to the radiotherapy prescription was 55%, and grade 3/4 acute and late esophageal and pulmonary toxic effects occurred in 4% and 7%; one patient died of radiation pneumonitis. Median and 5-year overall survival for patients randomly assigned to resection versus radiotherapy were 16.4 versus 17.5 months and 15.7% versus 14%, respectively (hazard ratio = 1.06, 95% Cl = 0.84 to 1.35). Rates of progression-free survival were also similar in both groups. Conclusion In selected patients with pathologically proven stage IIIA-N2 NSCLC and a response to induction chemotherapy, surgical resection did not improve overall or progression-free survival compared with radiotherapy. In view of its low morbidity and mortality, radiotherapy should be considered the preferred locoregional treatment for these patients.
引用
收藏
页码:442 / 450
页数:9
相关论文
共 50 条